![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Zoulim Fabien
Publisher: Informa Healthcare
ISSN: 1472-8214
Source: Expert Opinion on Emerging Drugs, Vol.12, Iss.2, 2007-05, pp. : 199-217
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Emerging pipeline drugs for hepatitis B infection
Expert Opinion on Emerging Drugs, Vol. 16, Iss. 4, 2011-12 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Drugs in Development for Hepatitis B
Drugs, Vol. 65, Iss. 11, 2005-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)